Search results
Earnings call: Curis reports on emavusertib progress in Q1 2024 By Investing.com
Investing.com· 17 hours agoThe company is advancing the drug as a treatment for various cancers, including relapsed/refractory...
Magnolia filmmaker will compete in multiple categories at film festival in France
Courier Post via Yahoo News· 1 hour ago“I couldn’t live with myself if I didn’t do it,” he said, while noting his decision caused some...
The Valley’s Jesse Lally Talks Dating ‘Beautiful Soul’ Lacy Nicole After Split from Michelle Saniei
People Magazine· 4 days agoThe news of the Bravo star's relationship with Lacy comes after he shared a photo on Instagram on...
Ashanti Shares Precious Moment She Surprised Nelly With Pregnancy News
VIBE via Yahoo News· 2 days agoAdditionally, the “Hot in Herre” icon adopted his niece and nephew, Shawn and Sydney Thomas, after...
CD7 expression tied to poorer outcomes with newly diagnosed leukemia
Medical Xpress· 5 days agoCD7 expression is associated with poorer outcomes in patients with newly diagnosed acute myeloid ...
North Kansas City High School Orchestra performs piece inspired by 5-year-old’s book
WDAF via Yahoo News· 1 day agoNORTH KANSAS CITY, Mo. — Five-year-old Quincy was diagnosed withLeukemia when she was three. She and...
Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
GuruFocus.com via Yahoo Finance· 3 hours agoA: Neil Gallagher, President and Head of R&D at Syndax, emphasized the importance of NCCN guidelines, noting that the initial approval for revumenib in KMT2A rearranged acute leukemias ...
Strengthening CAR-T therapy to work against solid tumors
Medical Xpress· 16 hours agoThe promising findings, reported in Science Advances, involve CAR-T cell therapy, which supercharges...
2 Incredible Growth Stocks to Buy Hand Over Fist
Motley Fool via Yahoo Finance· 21 hours agoThis year, Kura's stock has surged by 46% to date, a testament to investor confidence in the drugmaker's menin inhibitor, ziftomenib. This novel oral...
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and...
WTNH-TV New Haven· 23 hours agoSyndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an...